Clinical Trial Update: MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing medroxyprogesterone acetate (MPA) versus dydrogesterone for managing endometrial hyperplasia without atypia; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Hyperplasia Without Atypia

Drugs mentioned

• Dydrogesterone (dydrogesterone)
• Medroxyprogesterone acetate (MPA) (medroxyprogesterone acetate)

Snippet

Sponsor: Xiaojun Chen | Conditions: Endometrial Hyperplasia Without Atypia | Phase 3 | Status: COMPLETED